文献速递前列腺增生与排尿功能障碍

一项多中心研究评估新型闭环可穿戴胫神经调节系统治疗膀胱过度活动症与急迫性尿失禁的使用频率和疗效(FREEOAB)

A Multicenter Study Evaluating the FREquency of Use and Efficacy of a Novel Closed-Loop Wearable Tibial Neuromodulation System for Overactive Bladder and Urgency Urinary Incontinence (FREEOAB).
PubMed 文献 · Urology · 2023-11-07

这项为期12周的多中心开放标签单臂研究纳入96例膀胱过度活动症患者,使用经皮胫神经调节系统每周1次或3次,第12周3日排尿日记中每日排尿、失禁和急迫发作显著减少,生活质量改善超过所有问卷的最小临床重要差值,12个月结果仍稳健,装置相关不良事件轻微且无严重不良事件,12周平均治疗依从性88.5%。

要点

  • 96例膀胱过度活动症患者使用闭环可穿戴胫神经调节系统,第12周排尿日记参数显著改善。
  • 所有生活质量问卷改善均超过最小临床重要差值,12个月结果仍稳健。
  • 装置相关不良事件轻微,无装置相关严重不良事件,12周平均依从性88.5%。

核心结论

  • Avation装置治疗成人膀胱过度活动症和急迫性尿失禁显示出有前景的疗效,第12周排尿日记参数和生活质量指标均显著改善并持续至12个月。
  • 该装置安全性良好,依从性和患者满意度高,这种新型闭环可穿戴胫神经调节系统代表了膀胱控制治疗的重要进展,提供了一种无创、以患者为中心且可及性和易用性更好的替代方案。

研究设计与样本

  • 为期12周的多中心、开放标签、单臂研究,纳入膀胱过度活动症受试者96例,使用经皮胫神经调节系统,每周1次或3次,在第1、4、8、12周评估。

主要发现

  • 意向治疗人群96例(平均年龄60.8±13.0岁,女性88.5%),第12周3日排尿日记中每日排尿、失禁和急迫发作显著减少。
  • 所有生活质量问卷的改善均超过最小临床重要差值,12个月时长期结果仍稳健。
  • 装置相关不良事件轻微,无装置相关严重不良事件;12周平均治疗依从性为88.5%;报告对该装置的总体满意度高。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the effectiveness and safety of a novel wearable neuromodulation system incorporating embedded electromyographic evaluation, representing the first closed-loop wearable therapy for bladder control. METHODS: This 12-week, multicenter, open-label, single-arm study of subjects with overactive bladder assessed response of bladder diary parameters and quality of life (QOL) metrics. Subjects used the transcutaneous tibial neuromodulation system, either once or three times weekly, with evaluations at weeks 1, 4, 8, and 12. Enrolled subjects (N = 96) were assessed for changes in urinary frequency, urgency, and urgency urinary incontinence episodes, and QOL changes using various questionnaires. RESULTS: In the intent-to-treat population (N = 96, mean age 60.8 ± 13.0years, 88.5% female), significant reductions in 3-day diary parameters were observed for daily voids, incontinence, and urgency episodes at 12weeks. QOL improvements exceeded the minimal clinically important difference for all QOL questionnaires. Long-term results remained robust at 12months. Device-related adverse events were mild and there were no device-related serious adverse events. Mean therapy compliance at 12weeks was 88.5%. High satisfaction rates were reported for the device overall. CONCLUSION: The Avation device demonstrates promising efficacy in treating adults with overactive bladder and urge urinary incontinence. At 12weeks, both diary parameters and QOL indicators showed significant improvement and remained robust at 12months. The device had a favorable safety profile with high compliance and patient satisfaction. This novel, closed-loop wearable tibial neuromodulation system represents a significant advancement in bladder control therapy, offering a noninvasive, patient-centered alternative with improved accessibility and ease of use.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Goudelocke C, Sobol J, Poulos D, et al. A Multicenter Study Evaluating the FREquency of Use and Efficacy of a Novel Closed-Loop Wearable Tibial Neuromodulation System for Overactive Bladder and Urgency Urinary Incontinence (FREEOAB). Urology. 2023. PMID: 37944596. doi:10.1016/j.urology.2023.10.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。